Oropharyngeal cancer (OPC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Oropharyngeal squamous cell carcinoma, also known as OPSCC, is a type of cancer that affects the tonsils, soft palate, posterior and lateral pharyngeal walls, base and back third of the tongue, and the oropharynx, the middle portion of the pharynx that runs vertically from the soft palate to the superior area of the hyoid bone. Oropharyngeal cancer is the sixth most typical cancer worldwide. Males are more likely to get oropharyngeal cancer than females, and nearly 90% of oropharyngeal cancers that are HPV-positive are brought on by HPV 16. Significantly more HPV-associated OPSCC is present in the tonsils and base of the tongue. Radiotherapy and surgery are the two main treatment options for people with oropharyngeal cancer. Surgery or radiotherapy may be the main course of treatment, depending on how small and non-advanced the tumor is. However, when the disease has advanced or the tumor is larger, a combination of surgery and radiotherapy is used.

Description

Oropharyngeal squamous cell carcinoma, also known as OPSCC, is a type of cancer that affects the tonsils, soft palate, posterior and lateral pharyngeal walls, base and back third of the tongue, and the oropharynx, the middle portion of the pharynx that runs vertically from the soft palate to the superior area of the hyoid bone. The oropharynx is lined with squamous cell tumors, which are present in more than 90% of oropharyngeal malignancies. There are two types of oropharyngeal cancer: HPV-associated, which is caused by an oral human papillomavirus infection, and non-HPV-associated, which is primarily caused by tobacco and alcohol use. In addition to directly invading tissues, oropharyngeal cancer can also spread through the lymphatic and blood systems. Dysphagia, sore throat, and odynophagia are the three main indicators and symptoms of oropharyngeal cancer. The biopsy's findings are used to make the diagnosis of the diseased tissue. Treatment options include surgery, radiation therapy, chemotherapy, or a combination of these.

Oropharyngeal cancer (OPC) (Epidemiology)

Oropharyngeal cancer is the sixth most typical cancer in the world. Males are more likely than females to develop oropharyngeal cancers that are HPV-positive, which account for nearly 90% of all oropharyngeal cancer cases. There are significantly more HPV-associated OPSCCs in the tonsils and base of the tongue. The likelihood of developing HPV-associated OPSCC increases with age, lower rates of drinking and smoking, more men, and more oral sex partners. 53,000 individuals in the U.S. S. the American Cancer Society, have cancer. Oropharyngeal cancer strikes S. annually. There are 2:1 more man than women who develop this cancer. Caucasians and African Americans both go through it to the same degree. The average diagnosis age is 62. Oropharyngeal cancer occurs in about 25% of cases in people under the age of 55. This cancer rarely affects children. Over the past 20 years, the incidence of oropharyngeal cancer (OPC) has significantly increased, with almost all of this increase occurring in economically developed nations. This pattern highlights how the human papillomavirus (HPV), particularly in men, may be contributing to the increasing incidence of this disease.

Oropharyngeal cancer (OPC) -Current Market Size & Forecast Trends

The market for oropharyngeal cancer (OPC) treatment is projected to grow significantly, with estimates indicating a current value of approximately USD 2.2 billion in 2024, expected to reach around USD 4.7 billion by 2037, reflecting a compound annual growth rate (CAGR) of 6.7% during this period. This growth is driven by the increasing incidence of oropharyngeal cancer, particularly linked to human papillomavirus (HPV) infections, as well as advancements in treatment options such as immunotherapy and targeted therapies. The demand for early detection and innovative diagnostic tools is also contributing to market expansion, as healthcare providers focus on improving patient outcomes. Overall, the OPC market is well-positioned for substantial growth through 2035, supported by ongoing research and development efforts aimed at enhancing treatment strategies and increasing awareness of the disease.

Surgery and radiotherapy are the two main treatment options for people with oropharyngeal cancer. Radiotherapy or surgery may be the primary forms of treatment, depending on how small and non-advanced the tumor is. When the disease has advanced or the tumor is larger, however, surgery and radiotherapy are combined. It has been established that the first line of treatment for oropharyngeal carcinomas should consist of transoral laser microsurgery (TLM) and other minimally invasive methods. Advanced oropharyngeal cancer responds better to treatment when the daily radiation dose is divided into smaller-dose treatments. The term for this is hyperfractionated radiation therapy. Other resection methods include endoscopic laryngopharyngeal surgery, transoral robotic surgery, transoral video laryngoscopic surgery, and transoral ultrasound surgery. After surgery, patients who receive concurrent chemoradiotherapy or induction chemotherapy are more likely to survive. In comparison to radiotherapy alone, concurrent cisplatin-based chemotherapy and radiotherapy for unresectable tumors has been shown to improve survival. In stage III and stage IV non-metastatic oropharyngeal carcinomas, some studies have shown a similar prognostic profile of concurrent carboplatin/paclitaxel administration, but with fewer side effects. New surgical methods, such as transoral robotic surgery, are being studied for the treatment of oropharyngeal cancer. Transoral robotic surgery can be used to remove cancer that is hard to reach in the mouth and throat. A three-dimensional (3D) image produced by cameras mounted on a robot is visible to the surgeon. The surgeon uses a computer to operate the tiny instruments at the ends of the robot arms to remove the cancer. For the treatment of oropharyngeal cancer, pembrolizumab and nivolumab are two examples of PD-1 inhibitors under investigation.

Report Highlights

Oropharyngeal cancer (OPC) - Current Market Trends

Oropharyngeal cancer (OPC) - Current & Forecasted Cases across the G8 Countries

Oropharyngeal cancer (OPC) - Market Opportunities and Sales Potential for Agents

Oropharyngeal cancer (OPC) - Patient-based Market Forecast to 2035

Oropharyngeal cancer (OPC) - Untapped Business Opportunities

Oropharyngeal cancer (OPC) - Product Positioning Vis-a-vis Competitors' Products

Oropharyngeal cancer (OPC) - KOLs Insight